Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adverse Drug Reaction Early Detection System Implementation at Pharmacies
jRCT1070250064Recruiting
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ritlecitinib tosilate, capivasertib, momelotinib and finerenone, sponsored by None. Primary endpoint: Number of adverse drug reactions obtained by the system. Started Sep 2025; status: recruiting.
02
Drugs
ritlecitinib tosilatecapivasertibmomelotinibfinerenone
Beyond the preview
Go deeper on jRCT1070250064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1070250064.